Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Jetrea Market Revenue Growth Supported By A CAGR Of % Through 2030
The expansion observed during the historical period was driven by the constraints associated with surgical vitrectomy, a growing incidence of age-related eye conditions, initial clinical success with ocriplasmin, heightened awareness among ophthalmologists, and a rising need for non-surgical retinal treatments.
The expansion anticipated during the forecast period is driven by an aging worldwide demographic, the proliferation of retinal specialty clinics, enhanced screening for macular diseases, a growing inclination toward office-based treatment options, and ongoing advancements in ophthalmic enzymes. Key developments shaping this period include the rising implementation of pharmacologic vitreolysis, a stronger preference for minimally invasive retinal procedures, increased detection of vitreomacular conditions, a transition toward enzyme-based ophthalmic approaches, and the broadening of outpatient retinal healthcare services.
Download A Free Sample Report For Comprehensive Market Insights:
Jetrea Market Demand Drivers Creating New Revenue Opportunities
The growing frequency of retinal disorders is anticipated to boost the jetrea market in the coming period. Retinal diseases encompass various conditions impacting the retina, the eye’s light-sensitive layer at the back, which can result in vision impairment or blindness if not addressed. This rise in retinal disease cases is fueled by aging demographics, increasing diabetes rates, and heightened exposure to risk elements such as hypertension and lifestyle shifts. Jetrea, or ocriplasmin, is employed to manage vitreomacular traction and macular holes, targeting specific retinal issues linked to the growing prevalence of age-related and diabetic eye conditions. For example, in May 2024, The Royal College of Ophthalmologists, a UK-based public college, reported that the prevalence of sight loss and blindness from age-related macular degeneration (AMD) is expected to climb to 29.7% by 2050, compared to 23.1% in 2024, with the affected population rising from roughly 445,809 individuals to an estimated 1.23 million. Consequently, the increasing prevalence of retinal diseases is propelling the jetrea market forward.
Jetrea Market Driver: Rising Number Of Clinical Trials Driving Jetrea Market Growth
An expanding volume of clinical trials is predicted to drive the jetrea market’s growth in the future. Clinical trials are organized research investigations designed to assess the efficacy, safety, and potential adverse effects of medical therapies, drugs, or devices in human subjects. The surge in clinical trial numbers mirrors the escalating complexity of healthcare demands, scientific progress, and the widening scope of medical inquiry. Jetrea, through its innovative approach to treating symptomatic vitreomacular adhesion (sVMA), aids clinical trials by offering a focused therapeutic option that facilitates the assessment of effectiveness and safety in resolving this condition, thereby promoting retinal health research. As an illustration, in October 2024, ClinicalTrials.gov, a US government clinical trials registry, noted that 39,710 new studies were registered in 2023, bringing the cumulative total to 477,203 studies by year-end, compared to 38,023 new studies in 2022, which raised the cumulative total to 437,493 studies by the end of that year. Thus, the growing number of clinical trials is fueling the expansion of the jetrea market.
Jetrea Market Driver: The Rise Of Personalized Medicine Fueling Growth In The Jetrea Market
The ascent of personalized medicine is expected to accelerate the jetrea market’s growth moving forward. Personalized medicine represents a healthcare strategy that customizes treatment and medical plans based on each patient’s unique attributes, including genetic profile, environment, and lifestyle, to deliver the most effective and precise results. This trend toward personalized medicine is driven by progress in genomic technologies, a deeper comprehension of molecular biology, the wider availability of precision diagnostic tools, and a demand for targeted therapies that enhance patient outcomes while reducing side effects. Jetrea’s specific mechanism of action supports personalized medicine by addressing particular retinal conditions, such as symptomatic vitreomacular adhesion (sVMA), through a non-surgical, customized treatment that fits the distinct requirements of individual patients. For instance, in April 2025, the Drug Information Association (DIA) Global Forum, a US-based non-profit, stated that as of early 2025, the FDA has approved over 30 cell and gene therapies, with industry experts forecasting 30-50 additional approvals by 2030. Therefore, the rise of personalized medicine is propelling the jetrea market.
Jetrea Market Segment Outlook: Which Categories Are Expanding The Fastest?
The jetrea market covered in this report is segmented –
1) By Indication: Vitreomacular Traction, Symptomatoc Vitreomacular Adhesion, Combination Therapy
2) By Patient Demographics: Adult Patients, Elderly Patients, High-Risk Groups
3) By Distribution Channel: Direct Sales, Pharmaceutical Wholesalers, Online Pharmacies, International Markets
4) By End User: Ophthalmologists, Hospitals And Clinics, Outpatient Surgical Centres, Research Institutions
Jetrea Market Key Companies And Competitive Benchmarking
Major companies operating in the jetrea market are Oxurion NV (Formerly ThromboGenics Inc.)
Access The Complete Jetrea Market Report:
Jetrea Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the Jetrea market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the jetrea market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model